Jump to content

Delpazolid

From Wikipedia, the free encyclopedia

Delpazolid
Legal status
Legal status
  • Investigational
Identifiers
  • (5R)-3-[3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
CAS Number
PubChem CID
Chemical and physical data
FormulaC14H17FN4O3
Molar mass308.313 g·mol−1
3D model (JSmol)
  • CN1CCN(C=N1)C2=C(C=C(C=C2)N3C[C@@H](OC3=O)CO)F
  • InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1
  • Key:QLUWQAFDTNAYPN-LLVKDONJSA-N

Delpazolid (LCB01-0371) is an experimental antibiotic drug for the treatment of tuberculosis.[1][2]

References

[edit]
  1. ^ Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, et al. (February 2022). "Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis". Antimicrobial Agents and Chemotherapy. 66 (2): e0168421. doi:10.1128/AAC.01684-21. PMC 8846473. PMID 34871098.
  2. ^ Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, et al. (June 2023). "A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis". Trials. 24 (1): 382. doi:10.1186/s13063-023-07354-5. PMC 10243693. PMID 37280643.